Trial Profile
Pilot clinical trial with memantine for cognitive deficits in patients with multiple sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Cognition disorders; Multiple sclerosis
- Focus Pharmacodynamics; Therapeutic Use
- 08 Apr 2022 This trial has been completed (End Date: 30 Jun 2009), according to European Clinical Trials Database record.
- 07 Jun 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 09 Apr 2008 New trial record.